TriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is projected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect TriSalus Life Sciences to post earnings of ($0.35) per share for the quarter.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $5.65 on Wednesday. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $10.42. The business’s 50 day simple moving average is $5.36 and its two-hundred day simple moving average is $4.72. The firm has a market cap of $172.29 million, a P/E ratio of -2.27 and a beta of 0.48.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TLSI shares. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target for the company. Lake Street Capital started coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 target price for the company. Finally, Roth Mkm reissued a “buy” rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $11.56.

Insiders Place Their Bets

In related news, insider Sean Murphy purchased 15,000 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were acquired at an average price of $5.31 per share, for a total transaction of $79,650.00. Following the completion of the acquisition, the insider now directly owns 182,732 shares in the company, valued at approximately $970,306.92. The trade was a 8.94 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO James Emmett Young bought 6,000 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were bought at an average cost of $5.65 per share, for a total transaction of $33,900.00. Following the purchase, the chief financial officer now directly owns 30,000 shares in the company, valued at approximately $169,500. This represents a 25.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 54,856 shares of company stock valued at $294,608 in the last ninety days. Company insiders own 32.80% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.